{"id":"NCT01646268","sponsor":"UCB Pharma","briefTitle":"Rotigotine Versus Placebo As Double Blind Study To Evaluate The Efficacy In Early Stage Idiopathic Parkinson's Disease Patients","officialTitle":"A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Of The Efficacy And Safety Of The Rotigotine Transdermal Patch In Chinese Subjects With Early-stage Idiopathic Parkinson's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-07","primaryCompletion":"2014-05","completion":"2014-05","firstPosted":"2012-07-20","resultsPosted":"2015-08-11","lastUpdate":"2015-08-11"},"enrollment":249,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["IDIOPATHIC PARKINSON'S DISEASE"],"interventions":[{"type":"DRUG","name":"Rotigotine","otherNames":[]},{"type":"DRUG","name":"Placebo Patch","otherNames":[]}],"arms":[{"label":"Rotigotine","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective is to demonstrate that the Rotigotine transdermal patch is efficacious in Chinese subjects with early-stage idiopathic Parkinson's disease.","primaryOutcome":{"measure":"Change in the Sum of the Score From the Activities of Daily Living (ADL) Scale and Motor Examination in the Unified Parkinson's Disease Rating Scale (UPDRS) (Parts II+III, a UPDRS Subtotal) From Baseline to the End of Double-blind Maintenance Period","timeFrame":"From Baseline (Week 0) to end of Maintenance Period (up to Week 24)","effectByArm":[{"arm":"Rotigotine","deltaMin":-4.9,"sd":9.9},{"arm":"Placebo","deltaMin":-0.2,"sd":9.9}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"30 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":22},"locations":{"siteCount":24,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":124},"commonTop":["Dizziness","Nausea","Pruritus","Somnolence","Erythema"]}}